Merck & Co (MRK) | Stock Overview & Key Data
Merck & Co Performance Comparison
Stock Range
Today's Range
Low: $76.67
High: $82.88
on July 29, 2025
52 Week Range
Low: $73.31
High: $127.99
on May 15, 2025
on July 29, 2024
All-Time High: $134.63 on June 24, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$212.7B
EPS
6.88
P/E Ratio (TTM)
12.31
Forward P/E
9.01
P/B Ratio
4.41
PEG Ratio
9.01
Div. Yield
3.01%
ROE
39.29%
Beta
0.400
Debt to Equity
71.99
Financial Highlights
Profitability
Gross Margin
77.98%
Operating Margin
40.06%
Profit Margin
27.27%
Returns and Earnings
Return on Assets (TTM)
13.81%
Return on Equity (TTM)
39.29%
EBITDA
$26.6B
Net Income (TTM)
$17.4B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$25.29
Quarterly Revenue Growth (YoY)
-1.60%
Quarterly Earnings Growth (YoY)
6.70%
Dividend Information
Last 12-Month Dividend
$2.39
Current Dividend Yield
3.01%
3-Year Average Dividend Yield
0.71%
3-Year Average Annual Dividend
$2.77
3-Year Total Dividends
$8.31
Ex-Dividend Date
March 17, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Merck & Co MRK | 212.71B Mega-cap | 1.25% | 4.38% | -2.46% | -15.92% | -16.68% | -28.27% | -5.47% | 6.88% |
| Eli Lilly and LLY | 729.58B Mega-cap | -1.74% | -2.13% | -13.81% | -5.12% | -1.94% | -5.16% | 153.20% | 398.89% |
| Johnson & Johnson JNJ | 400.31B Mega-cap | 0.11% | 10.06% | 7.83% | 11.22% | 16.73% | 2.42% | -1.75% | 13.13% |
| AbbVie ABBV | 336.11B Mega-cap | 2.20% | 3.02% | -1.18% | 9.11% | 6.56% | 1.02% | 38.53% | 105.79% |
| Amgen AMGN | 162.01B Large-cap | -0.70% | 8.72% | 5.20% | 7.77% | 17.08% | -9.11% | 23.27% | 26.12% |
| Gilead Sciences GILD | 144.55B Large-cap | 3.69% | 3.03% | 9.62% | 19.50% | 24.33% | 48.80% | 86.99% | 64.72% |
Ownership & Short Interest
Insider Ownership
0.06%
Institutional Ownership
80.50%
Shares Short
29M
Short Ratio
1.61
Short % of Shares Outstanding
1.28%
Average 10-Day Volume
11M
Average 90-Day Volume
16M
Merck & Co Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Merck & Co would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is MRK's 52-week high and low?
- In the last 52 weeks, Merck & Co reached a high of $127.99 (on July 29, 2024) and a low of $73.31 (on May 15, 2025).
- What is the market cap and P/E ratio for MRK?
- Curious about Merck & Co's size and valuation? Its market capitalization stands at 212.71B. When it comes to valuation, the P/E ratio (trailing twelve months) is 12.31, and the forward P/E (looking ahead) is 9.01.
- Does MRK pay dividends? If so, what's the yield?
- Yes, Merck & Co is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.01%, and the company has paid an average of $2.77 per share annually over the past 3 years.
- Who are Merck & Co's main competitors or similar companies to consider before investing?
When looking at Merck & Co, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Eli Lilly and
LLY729.58B Healthcare Drug Manufacturers - General -5.16% 153.20% Johnson & Johnson
JNJ400.31B Healthcare Drug Manufacturers - General 2.42% -1.75% AbbVie
ABBV336.11B Healthcare Drug Manufacturers - General 1.02% 38.53% Amgen
AMGN162.01B Healthcare Drug Manufacturers - General -9.11% 23.27% Gilead Sciences
GILD144.55B Healthcare Drug Manufacturers - General 48.80% 86.99% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Merck & Co., Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Merck & Co's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 39.29%, the Debt to Equity ratio from the most recent quarter is 71.99, and its Gross Profit Margin stands at 77.98%.
- What is the recent revenue and earnings growth for MRK?
- Looking at Merck & Co's growth, its revenue over the trailing twelve months (TTM) was $64B. Compared to the same quarter last year (YoY), quarterly revenue grew by -1.60%, and quarterly earnings saw a YoY growth of 6.70%.
- How much of MRK stock is held by insiders and institutions?
- Wondering who owns Merck & Co stock? Company insiders (like executives and directors) hold about 0.06% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 80.50%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.